ArticleJournal of molecular medicine (Berlin, Germany)2026
Vasoactive intestinal peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Current therapies for osteoarthritis (OA) focus on symptom management, rather than halting disease progression. Vasoactive intestinal peptide (VIP) has shown promising effects in musculoskeletal diseases, preserving joint integrity and modulating inflammation. This study investigates the potential of VIP to promote chondrogenic differentiation of human bone marrow mesenchymal stem cells (BM-hMSC) and to modulate inflammatory and cartilage extracellular matrix (ECM)-degrading mediators in human osteoarthritis articular chondrocytes (OA-hAC). BM-hMSC from healthy donors were cultured in 3D pellet sytems under chondrogenic conditions, with or without VIP, for up to 21 days. Chondrogenesis was evaluated through the expression of key markers (SOX9, COL2A1, and ACAN), hypertrophic markers (RUNX2, COL10A1, and MMP13), and glycosaminoglycans (GAG). VIP accelerated chondrogenic differentiation by inducing earlier mRNA and protein expression of chondrogenic markers and enhancing GAG production. In parallel, OA-hAC were cultured in 3D alginate microbeads and stimulated with fibronectin fragments (Fn-fs) in the presence and absence of VIP. We analysed the effects of VIP on cell proliferation, GAG production, and the modulation of complement components (C1R and C3) and matrix metalloproteinases (MMP1, MMP3, MMP9, and MMP13). VIP increased cell proliferation and GAG deposition while significantly reducing the production of complement component C1R and matrix metalloproteinases MMP1 and MMP13. Overall, these findings demonstrate that VIP advances chondrogenesis and exerts anti-inflammatory and anti-catabolic effects in 3D culture models. This study highlights the potential of VIP as a therapeutic agent and supports the combination of MSC-based approaches with VIP as a promising strategy to enhance cartilage regeneration and slow OA progression.
Indexed as
Identifiers
42178419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.